| Year |
Citation |
Score |
| 2020 |
Liu X, Jiang Y, Nowak B, Ichikawa S, Ohtawa M, Matsuda A, Plunkett W. Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination. Cancer Chemotherapy and Pharmacology. PMID 32072218 DOI: 10.1007/S00280-020-04035-X |
0.38 |
|
| 2019 |
Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS. Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia. Cancer Immunology Research. PMID 31530560 DOI: 10.1158/2326-6066.Cir-19-0152 |
0.331 |
|
| 2019 |
Liu X, Jiang Y, Takata KI, Nowak B, Liu C, Wood RD, Hittelman WN, Plunkett W. CNDAC-induced DNA double strand breaks cause aberrant mitosis prior to cell death. Molecular Cancer Therapeutics. PMID 31501277 DOI: 10.1158/1535-7163.Mct-18-1380 |
0.466 |
|
| 2019 |
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, ... ... Plunkett W, et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. The New England Journal of Medicine. 380: 2095-2103. PMID 31141631 DOI: 10.1056/Nejmoa1900574 |
0.361 |
|
| 2019 |
Lai TH, Mitchell S, Wu PJ, Orwick S, Liu C, Ravikrishnan J, Woyach J, Mims A, Plunkett W, Puduvalli VK, Byrd JC, Lapalombella R, Sampath D. HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics. Leukemia & Lymphoma. 1-4. PMID 30773117 DOI: 10.1080/10428194.2019.1571197 |
0.433 |
|
| 2019 |
Chen R, Zhu M, Chaudhari RR, Robles O, Chen Y, Skillern W, Qin Q, Wierda WG, Zhang S, Hull KG, Romo D, Plunkett W. Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia. Leukemia. PMID 30700841 DOI: 10.1038/S41375-018-0364-X |
0.38 |
|
| 2019 |
Wierda WG, Lee ST, Chen R, Zheleva D, Blake D, Chiao JH, Plunkett W. A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Blood. 134: 1761-1761. DOI: 10.1182/Blood-2019-128956 |
0.354 |
|
| 2018 |
Elsayed AH, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro RC, Pounds SB, Lamba JK. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics. PMID 30088438 DOI: 10.2217/Pgs-2018-0086 |
0.351 |
|
| 2018 |
Ravikrishnan J, Lai T, Mitchell SR, Wu P, Orwick S, Liu C, Woyach JA, Mims AS, Plunkett W, Puduvalli VK, Byrd JC, Lapalombella R, Sampath D. Using HSP90 Inhibitors to Target DNA Repair Proteins in AML Blood. 132: 5144-5144. DOI: 10.1182/Blood-2018-99-116485 |
0.399 |
|
| 2018 |
Chen R, Chen Y, Frame S, Blake D, Wierda WG, Zheleva D, Plunkett W. Abstract 3905: Strategic combination of the cyclin-dependent kinase inhibitor CYC065 with venetoclax to target anti-apoptotic proteins in chronic lymphocytic leukemia Cancer Research. 78: 3905-3905. DOI: 10.1158/1538-7445.Am2018-3905 |
0.443 |
|
| 2017 |
Al Abo M, Sasanuma H, Liu X, Rajapakse VN, Huang SN, Kiselev E, Takeda S, Plunkett W, Pommier Y. TDP1 is critical for the repair of DNA breaks induced by sapacitabine, a nucleoside also targeting ATM- and BRCA-deficient tumors. Molecular Cancer Therapeutics. PMID 28802254 DOI: 10.1158/1535-7163.Mct-17-0110 |
0.371 |
|
| 2017 |
Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, et al. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leukemia & Lymphoma. 1-8. PMID 28718728 DOI: 10.1080/10428194.2017.1349907 |
0.353 |
|
| 2017 |
Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, et al. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. PMID 28708931 DOI: 10.1002/Cncr.30883 |
0.35 |
|
| 2017 |
Issa GC, Kantarjian HM, Short NJ, Ravandi F, Huang X, Garcia-Manero G, Plunkett W, Gandhi V, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, et al. Idarubicin and cytarabine with clofarabine or fludarabine in adults with newly diagnosed acute myeloid leukemia: Updated results of a randomized phase II study. Journal of Clinical Oncology. 35: 7037-7037. DOI: 10.1200/Jco.2017.35.15_Suppl.7037 |
0.321 |
|
| 2016 |
Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R, Reiff S, El-Gamal D, Larkin K, Johnson AJ, Lapalombella R, Lehman A, Plunkett W, Byrd JC, Blachly JS, et al. Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood. PMID 27756747 DOI: 10.1182/Blood-2016-07-727750 |
0.36 |
|
| 2016 |
Liu X, Jiang Y, Nowak B, Hargis S, Plunkett W. Mechanism-based drug combinations with the DNA-strand-breaking nucleoside analog, CNDAC. Molecular Cancer Therapeutics. PMID 27474148 DOI: 10.1158/1535-7163.Mct-15-0801 |
0.499 |
|
| 2016 |
Jouanneau M, McClary B, Reyes JC, Chen R, Chen Y, Plunkett W, Cheng X, Milinichik AZ, Albone EF, Liu JO, Romo D. Derivatization of agelastatin A leading to bioactive analogs and a trifunctional probe. Bioorganic & Medicinal Chemistry Letters. PMID 26951751 DOI: 10.1016/J.Bmcl.2016.02.051 |
0.334 |
|
| 2016 |
Lai TH, Ewald B, Zecevic A, Liu C, Sulda M, Papaioannou D, Garzon R, Blachly JS, Plunkett W, Sampath D. HDAC inhibition induces microRNA-182 which targets Rad51 and impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26858310 DOI: 10.1158/1078-0432.Ccr-15-1063 |
0.79 |
|
| 2016 |
Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, Borthakur G, Jain N, Waukau J, Kwari M, Anderson BD, Iizuka K, Jin C, Zhang C, Ravandi F, ... Plunkett W, et al. Phase I/II Study of DFP-10917 in Relapsed/Refractory AML Demonstrates Efficacy and Safety Profile Suitable for Phase III Study Blood. 128: 2822-2822. DOI: 10.1182/Blood.V128.22.2822.2822 |
0.328 |
|
| 2016 |
Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Plunkett W. Abstract 4633: The DNA strand breaking nucleoside analogue sapacitabine sensitizes Brca2-deficient ovarian cancer cells and synergizes with PARP inhibitors Cancer Research. 76: 4633-4633. DOI: 10.1158/1538-7445.Am2016-4633 |
0.46 |
|
| 2016 |
Jiang Y, Liu X, Chen H, Do K, Su X, Wierda W, Keating M, Plunkett W. Abstract 408: ATM function and mutation in CLL 11q deletion samples Cancer Research. 76: 408-408. DOI: 10.1158/1538-7445.Am2016-408 |
0.374 |
|
| 2015 |
Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ. Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. PMID 26492934 DOI: 10.1182/Blood-2015-09-667675 |
0.307 |
|
| 2015 |
Plunkett W. Arginine addiction in AML. Blood. 125: 3971-2. PMID 26113532 DOI: 10.1182/Blood-2015-05-643411 |
0.318 |
|
| 2015 |
Yeh YY, Chen R, Hessler J, Mahoney E, Lehman AM, Heerema NA, Grever MR, Plunkett W, Byrd JC, Johnson AJ. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. Oncotarget. 6: 2667-79. PMID 25596730 DOI: 10.18632/Oncotarget.2096 |
0.384 |
|
| 2015 |
Kantarjian HM, Jabbour E, Garcia-Manero G, Kadia TM, Dinardo CD, Daver NG, Borthakur G, Jain N, Waukau J, Kwari M, Anderson BD, Iizuka K, Jin C, Plunkett W. First report of a phase I/II study of DFP-10917, a nucleoside analog, given by continuous infusion (CI) in patients (pts) with relapsed or refractory acute leukemia. Journal of Clinical Oncology. 33: 7077-7077. DOI: 10.1200/Jco.2015.33.15_Suppl.7077 |
0.357 |
|
| 2015 |
Kantarjian H, Jabbour E, Garcia-Manero G, Kadia T, DiNardo C, Daver N, Borthakur G, Jain N, Waukau J, Kwari M, Anderson BD, Iizuka K, Jin C, Plunkett W. Results of a Phase I/II Study of DFP-10917, a Nucleoside Analog, Given By Continuous Infusion (CI) in Patients (pts) with Relapsed or Refractory Acute Leukemia Blood. 126: 3804-3804. DOI: 10.1182/Blood.V126.23.3804.3804 |
0.341 |
|
| 2015 |
Lai T, Zecevic A, Ewald B, Chaomei L, Rizzotto L, Sulda M, Papaioannou D, Garzon R, Plunkett W, Sampath D. HDAC Inhibition Induces microRNA-182 Which Targets Rad51 Protein and Impairs Homologous Recombination Repair to Sensitize Cells to the Double Strand Break Inducing Nucleoside Analog, Sapacitabine in AML Blood. 126: 3639-3639. DOI: 10.1182/Blood.V126.23.3639.3639 |
0.777 |
|
| 2015 |
Liu X, Jiang Y, Nowak B, Tikhomirova D, Plunkett W. Abstract 2551: Brca1-deficient ovarian cancer cells are sensitized to the DNA-strand-breaking nucleoside analog sapacitabine that synergizes with PARP inhibition Cancer Research. 75: 2551-2551. DOI: 10.1158/1538-7445.Am2015-2551 |
0.463 |
|
| 2015 |
Jiang Y, Liu X, Plunkett W. Abstract 2550: FANCA protein is involved in the homologous recombination repair of sapacitabine-induced DNA damage Cancer Research. 75: 2550-2550. DOI: 10.1158/1538-7445.Am2015-2550 |
0.482 |
|
| 2015 |
Abo MA, Liu X, Plunkett W, Pommier Y. Abstract 2549: Tyrosyl-DNA phosphodiesterase 1 (TDP1) is critical for the repair of DNA breaks induced by sapacitabine, a nucleoside antimetabolite in clinical trials targeted to ATM- and BRCA-deficient tumors Cancer Research. 75: 2549-2549. DOI: 10.1158/1538-7445.Am2015-2549 |
0.468 |
|
| 2015 |
Chen R, Zhu M, Chen Y, Skillern W, Wierda WG, Hull K, Romo D, Plunkett W. Abstract 1765: Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia Cancer Research. 75: 1765-1765. DOI: 10.1158/1538-7445.Am2015-1765 |
0.401 |
|
| 2014 |
Tam CS, O'Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, Do KA, Cortes J, Khouri I, Kantarjian H, Lerner S, Keating MJ. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 124: 3059-64. PMID 25281606 DOI: 10.1182/Blood-2014-06-583765 |
0.318 |
|
| 2014 |
Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1735-40. PMID 24501394 DOI: 10.1158/1078-0432.Ccr-13-1283 |
0.374 |
|
| 2014 |
Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Lymphoma, Myeloma & Leukemia. 14: 231-8. PMID 24440659 DOI: 10.1016/J.Clml.2013.12.001 |
0.445 |
|
| 2014 |
Jiang Y, Liu X, Chestang A, Plunkett W. Abstract 5454: Inhibition of Bcr-Abl tyrosine kinase sensitizes cells to sapacitabine Cancer Research. 74: 5454-5454. DOI: 10.1158/1538-7445.Am2014-5454 |
0.474 |
|
| 2014 |
Chen R, Chen Y, Ghia EM, Rassenti L, Kipps T, Keating MJ, Wierda WG, Plunkett W. Abstract 343: Targeting SF3B1 mediated splicing control of Mcl-1 in chronic lymphocytic leukemia Cancer Research. 74: 343-343. DOI: 10.1158/1538-7445.Am2014-343 |
0.383 |
|
| 2013 |
Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 14: 1449-66. PMID 24024897 DOI: 10.2217/Pgs.13.131 |
0.349 |
|
| 2013 |
Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leukemia Research. 37: 1461-7. PMID 23993427 DOI: 10.1016/J.Leukres.2013.07.034 |
0.395 |
|
| 2013 |
Zecevic A, Ewald B, Hayes M, Liu C, Marcucci G, Plunkett W. Panobinostat, An Oral Pan-Histone Deacetylase (HDAC) Inhibitor Activates a Microrna Signature That Targets Rad51 To Attenuate Homologous DNA Repair and Sensitize AML Cells To Sapacitabine Blood. 122: 822-822. DOI: 10.1182/Blood.V122.21.822.822 |
0.787 |
|
| 2013 |
Leung B, Chen Y, Plunkett W. Activities and Mechanism Based Combinations Of Omacetaxine In Acute Myeloid Leukemia Blood. 122: 1288-1288. DOI: 10.1182/Blood.V122.21.1288.1288 |
0.455 |
|
| 2013 |
Jiang Y, Liu X, Wen S, Do K, Su X, Keating MJ, Wierda W, Plunkett W. Abstract 3528: Quantitation of ATM function in primary CLL cells. Cancer Research. 73: 3528-3528. DOI: 10.1158/1538-7445.Am2013-3528 |
0.431 |
|
| 2013 |
Liu X, Nowak B, Jiang Y, Hittelman W, Plunkett W. Abstract 3418: Mechanism of cell death induced by the DNA strand-breaking nucleoside analogue CNDAC. Cancer Research. 73: 3418-3418. DOI: 10.1158/1538-7445.Am2013-3418 |
0.482 |
|
| 2012 |
Liu XJ, Nowak B, Wang YQ, Plunkett W. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. Chinese Journal of Cancer. 31: 373-80. PMID 22739266 DOI: 10.5732/cjc.012.10077 |
0.36 |
|
| 2012 |
Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clinical Lymphoma, Myeloma & Leukemia. 12: 244-51. PMID 22534616 DOI: 10.1016/J.Clml.2012.03.003 |
0.345 |
|
| 2012 |
Liu X, Kantarjian H, Plunkett W. Sapacitabine for cancer. Expert Opinion On Investigational Drugs. 21: 541-55. PMID 22329458 DOI: 10.1517/13543784.2012.660249 |
0.322 |
|
| 2012 |
Borthakur G, Cortes JE, O'Brien SM, Kadia TM, Estrov Z, Faderl S, Ravandi F, Gandhi V, Plunkett W, Bass J, Brandt M, Kantarjian H. Effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on relapse-free survival in patients with newly diagnosed core-binding factor acute myelogenous leukemia. Journal of Clinical Oncology. 30: 6528-6528. DOI: 10.1200/Jco.2012.30.15_Suppl.6528 |
0.347 |
|
| 2012 |
Keating MJ, Tam CS, Wierda WG, O'Brien S, Thomas DA, Cortes JE, Lerner S, Plunkett W. Is Chronic Lymphocytic Leukemia Still Incurable Blood. 120: 3929-3929. DOI: 10.1182/Blood.V120.21.3929.3929 |
0.325 |
|
| 2012 |
Liu X, Nowak B, Hargis S, Plunkett W. Abstract 5667: Mechanism-based combinations of agents impacting the homologous recombination and nucleotide excision repair pathways Cancer Research. 72: 5667-5667. DOI: 10.1158/1538-7445.Am2012-5667 |
0.481 |
|
| 2012 |
Chen R, Tsai J, Chen Y, Burrows F, Wierda W, Plunkett W. Abstract 2808: Mechanism of action of the multikinase inhibitor TG02 in chronic lymphocytic leukemia Cancer Research. 72: 2808-2808. DOI: 10.1158/1538-7445.Am2012-2808 |
0.404 |
|
| 2012 |
Sulda ML, Liu C, Keating MJ, Wierda WG, Plunkett W, Sampath D. Abstract 120: Epigenetic silencing of miR-17 and miR-20a in chronic lymphocytic leukemia Cancer Research. 72: 120-120. DOI: 10.1158/1538-7445.Am2012-120 |
0.312 |
|
| 2011 |
Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia. 26: 443-50. PMID 21904380 DOI: 10.1038/Leu.2011.246 |
0.391 |
|
| 2011 |
Zecevic A, Sampath D, Ewald B, Chen R, Wierda W, Plunkett W. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4731-41. PMID 21632856 DOI: 10.1158/1078-0432.Ccr-10-2561 |
0.769 |
|
| 2011 |
Guo L, Liu X, Jiang Y, Nishikawa K, Plunkett W. DNA-dependent protein kinase and ataxia telangiectasia mutated (ATM) promote cell survival in response to NK314, a topoisomerase IIα inhibitor. Molecular Pharmacology. 80: 321-7. PMID 21546556 DOI: 10.1124/mol.109.057125 |
0.376 |
|
| 2011 |
Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood. 117: 156-64. PMID 20971952 DOI: 10.1182/Blood-2010-01-262808 |
0.428 |
|
| 2011 |
Tsimberidou AM, Keating MJ, Estey EH, Jabbour E, Zweidler-McKay P, Plunkett W, Kantarjian HM, Borthakur G. Phase I-II Study of Fludarabine, Cytarabine and Oxaliplatin In Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Blood. 118: 4274-4274. DOI: 10.1182/Blood.V118.21.4274.4274 |
0.336 |
|
| 2011 |
Kadia T, Gandhi V, Thomas DA, Ravandi F, Plunkett W, Ayres ML, Chen Y, Zacharian G, Borthakur G, Kantarjian HM, Keating MJ. Phase I Study of Continuous-Infusion Nelarabine in Patients with Advanced Lymphoid Malignancies Blood. 118: 4239-4239. DOI: 10.1182/Blood.V118.21.4239.4239 |
0.354 |
|
| 2011 |
Daver N, Kantarjian HM, Garcia-Manero G, Cortes JE, Ravandi F, Plunkett W, Gandhi V, Faderl S, o'Brien S, Borthakur G, Kadia T, Burger JA, Konopleva M, Brandt M, Huang X, et al. Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia, Blood. 118: 3629-3629. DOI: 10.1182/Blood.V118.21.3629.3629 |
0.344 |
|
| 2011 |
Carter BZ, Mak DH, Shi Y, Fidler JM, Chen R, Ling X, Plunkett W, Andreeff M. MRx102, a Novel Triptolide Analogue, Has Low Nanomolar Activity Against AML Stem/Progenitor Cells in Vitro and in a Murine Model of AML Blood. 118: 1547-1547. DOI: 10.1182/Blood.V118.21.1547.1547 |
0.399 |
|
| 2011 |
Liu X, Nowak B, Matsuda A, Plunkett W. Abstract 962: Mechanism-based drug combinations with the DNA-strand-breaking nucleoside analog CNDAC Cancer Research. 71: 962-962. DOI: 10.1158/1538-7445.Am2011-962 |
0.506 |
|
| 2011 |
Sampath D, Liu C, Wierda W, Plunkett W, Keating MJ. Abstract 1191: Role of histone deacetylases in silencing functionally relevant microRNAs in CLL Cancer Research. 71: 1191-1191. DOI: 10.1158/1538-7445.Am2011-1191 |
0.316 |
|
| 2011 |
Liu X, Nowak B, Hargis S, Plunkett W. 5.52 The DNA-Strand-Breaking Nucleoside Analog Sapacitabine: Mechanism-Based Drug Combinations Clinical Lymphoma Myeloma and Leukemia. 11: S280. DOI: 10.1016/J.Clml.2011.09.206 |
0.378 |
|
| 2011 |
Jiang Y, Liu X, Keating MJ, Wierda W, Plunkett W. 2.54 Targeting Refractory CLL Lacking ATM Function with Sapacitabine-Containing Therapy Clinical Lymphoma, Myeloma & Leukemia. 11. DOI: 10.1016/J.Clml.2011.09.087 |
0.409 |
|
| 2011 |
Chen R, Chen Y, Plunkett W. 2.30 Transcriptional Inhibition: Mechanism of Action for CDK Inhibitors in CLL to Overcome Microenvironment-Mediated Protection Clinical Lymphoma, Myeloma & Leukemia. 11. DOI: 10.1016/J.Clml.2011.09.063 |
0.332 |
|
| 2010 |
Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, Tsai CY, Shi X, Schwarzer D, Plunkett W, Aronow B, Gozani O, Fischle W, Hung MC, Patel DJ, et al. TRIM24 links a non-canonical histone signature to breast cancer. Nature. 468: 927-32. PMID 21164480 DOI: 10.1038/Nature09542 |
0.562 |
|
| 2010 |
Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W, Kantarjian H. Clofarabine in leukemia. Expert Review of Hematology. 3: 15-22. PMID 21082931 DOI: 10.1586/Ehm.09.70 |
0.43 |
|
| 2010 |
Liu X, Wang Y, Benaissa S, Matsuda A, Kantarjian H, Estrov Z, Plunkett W. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood. 116: 1737-46. PMID 20479284 DOI: 10.1182/Blood-2009-05-220376 |
0.496 |
|
| 2010 |
Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, Green SR, Chiao JH, Boone PA, Cortes J, Plunkett W. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 285-91. PMID 19933907 DOI: 10.1200/Jco.2009.25.0209 |
0.311 |
|
| 2010 |
Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Kantarjian HM, Keating MJ. Results of a Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab (OFAR) Combination Therapy In Patients with Aggressive, Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Richter Syndrome (RS) Blood. 116: 923-923. DOI: 10.1182/Blood.V116.21.923.923 |
0.361 |
|
| 2010 |
Lamba J, Mitra A, Crews K, Stanley P, Cao X, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Pathway Based Pharmacogenomics of Cytarabine In Pediatric Acute Myeloid Leukemia Blood. 116: 294-294. DOI: 10.1182/Blood.V116.21.294.294 |
0.36 |
|
| 2010 |
Chen R, Guo L, Chen Y, Jiang Y, Wierda WG, Plunkett W. Reducing Mcl-1 by Homoharringtonine Induces Apoptosis In Chronic Lymphocytic Leukemia Cells Blood. 116: 2896-2896. DOI: 10.1182/Blood.V116.21.2896.2896 |
0.425 |
|
| 2010 |
Liu X, Jiang Y, Matsuda A, Plunkett W. Homologous Recombination Repair of DNA Strand Breaks Induced by the Nucleoside Analogue CNDAG. Blood. 116: 1189-1189. DOI: 10.1182/Blood.V116.21.1189.1189 |
0.495 |
|
| 2010 |
Zecevic A, Ewald B, Sampath D, Wierda W, Plunkett W. Abstract 5379: Mechanism of fludarabine and oxaliplatin combined activity depends on the activity of XPF endonuclease Cancer Research. 70: 5379-5379. DOI: 10.1158/1538-7445.Am10-5379 |
0.8 |
|
| 2010 |
Chen R, Chen Y, Green SR, Wierda WG, Plunkett W. Abstract 4431: A novel derivative of the Cdk inhibitor roscovitine that induces apoptosis in CLL and overcomes stromal cell-mediated protection Cancer Research. 70: 4431-4431. DOI: 10.1158/1538-7445.Am10-4431 |
0.422 |
|
| 2010 |
Liu X, Matsuda A, Plunkett W. Abstract 3638: DNA strand breaks induced by 2′-C-cyano-2′-deoxy-nucleoside analogs are repaired by homologous recombination Cancer Research. 70: 3638-3638. DOI: 10.1158/1538-7445.Am10-3638 |
0.43 |
|
| 2009 |
Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 114: 4441-50. PMID 19762485 DOI: 10.1182/Blood-2009-07-233718 |
0.364 |
|
| 2009 |
Tsai CY, Ray AS, Tumas DB, Keating MJ, Reiser H, Plunkett W. Targeting DNA repair in chronic lymphocytic leukemia cells with a novel acyclic nucleotide analogue, GS-9219. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3760-9. PMID 19435836 DOI: 10.1158/1078-0432.Ccr-08-2848 |
0.684 |
|
| 2009 |
Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood. 113: 3744-53. PMID 19096009 DOI: 10.1182/Blood-2008-09-178707 |
0.77 |
|
| 2009 |
Lamba JK, Mitra A, Crews K, Pounds S, Cao X, Gandhi V, Plunkett W, Rubnitz J, Ribeiro RC. 5'Nucleotidase (NT5C2) Genotype Influences Leukemic Blast Concentration of Ara-CTP in Pediatric Patients with Acute Myeloid Leukemia. Blood. 114: 593-593. DOI: 10.1182/Blood.V114.22.593.593 |
0.364 |
|
| 2009 |
Tsimberidou A, Wierda W, Plunkett W, O'Brien S, Kipps TJ, Jones JA, Smith S, Jalayer A, Kantarjian HM, Keating M. Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS). Blood. 114: 3443-3443. DOI: 10.1182/Blood.V114.22.3443.3443 |
0.367 |
|
| 2009 |
Lamba JK, Crews K, Pounds S, Cao X, Gandhi V, Plunkett W, Baker SD, Pui C, Campana D, Downing JR, Rubnitz J, Ribeiro RC. Gene Expression Patterns Associated with Cytarabine Pharmacology and Outcome in Pediatric Acute Myeloid Leukemia. Blood. 114: 114-114. DOI: 10.1182/Blood.V114.22.114.114 |
0.359 |
|
| 2008 |
Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene. 27: 6522-37. PMID 18955977 DOI: 10.1038/Onc.2008.316 |
0.789 |
|
| 2008 |
Ewald B, Sampath D, Plunkett W. ATM and the Mre11-Rad50-Nbs1 complex respond to nucleoside analogue-induced stalled replication forks and contribute to drug resistance. Cancer Research. 68: 7947-55. PMID 18829552 DOI: 10.1158/0008-5472.Can-08-0971 |
0.784 |
|
| 2008 |
Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, Huang P. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood. 112: 1912-22. PMID 18574029 DOI: 10.1182/Blood-2008-04-149815 |
0.398 |
|
| 2008 |
Wang Y, Liu X, Matsuda A, Plunkett W. Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair. Cancer Research. 68: 3881-9. PMID 18483273 DOI: 10.1158/0008-5472.Can-07-6885 |
0.438 |
|
| 2008 |
Reiser H, Wang J, Chong L, Watkins WJ, Ray AS, Shibata R, Birkus G, Cihlar T, Wu S, Li B, Liu X, Henne IN, Wolfgang GH, Desai M, Rhodes GR, ... ... Plunkett W, et al. GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2824-32. PMID 18451250 DOI: 10.1158/1078-0432.Ccr-07-2061 |
0.331 |
|
| 2008 |
Liu X, Matsuda A, Plunkett W. Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine. Molecular Cancer Therapeutics. 7: 133-42. PMID 18202016 DOI: 10.1158/1535-7163.Mct-07-0416 |
0.432 |
|
| 2008 |
Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 196-203. PMID 18182662 DOI: 10.1200/Jco.2007.11.8513 |
0.338 |
|
| 2008 |
Wierda WG, Chen R, Plunkett W, Coutre S, Badros AZ, Popplewell L, Siegel D, Sinha R, Harvey D, Fox J, Mahadocon K, Kegley P, Bolton MG. A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor, in Chronic Lymphocytic Leukemia and Multiple Myeloma Blood. 112: 3178-3178. DOI: 10.1182/Blood.V112.11.3178.3178 |
0.369 |
|
| 2008 |
Ravandi F, Sampath D, Plunkett W, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, Alvarez V, Becker MD, List AF, Sebti S, Kantarjian HM, Lancet J. Phase I Study of the Akt-Inhibitor Triciribine Phosphate Monohydrate in Patients with Advanced Hematologic Malignancy Blood. 112: 2987-2987. DOI: 10.1182/Blood.V112.11.2987.2987 |
0.397 |
|
| 2007 |
Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. The Journal of Pharmacology and Experimental Therapeutics. 323: 935-45. PMID 17855478 DOI: 10.1124/Jpet.107.128595 |
0.303 |
|
| 2007 |
Sampath D, Plunkett W. The role of DNA repair in chronic lymphocytic leukemia pathogenesis and chemotherapy resistance. Current Oncology Reports. 9: 361-7. PMID 17706164 |
0.389 |
|
| 2007 |
Guo L, Liu X, Nishikawa K, Plunkett W. Inhibition of topoisomerase IIalpha and G2 cell cycle arrest by NK314, a novel benzo[c]phenanthridine currently in clinical trials. Molecular Cancer Therapeutics. 6: 1501-8. PMID 17513599 DOI: 10.1158/1535-7163.Mct-06-0780 |
0.472 |
|
| 2007 |
Ewald B, Sampath D, Plunkett W. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Molecular Cancer Therapeutics. 6: 1239-48. PMID 17406032 DOI: 10.1158/1535-7163.Mct-06-0633 |
0.762 |
|
| 2007 |
Ravandi F, Lancet J, Giles F, Plunkett W, Williams B, Burton M, Faderl S, Estrov Z, Borthakur G, Akinsanmi L, Kantarjian H. Phase I Study of Triciribine Phosphate Monohydrate, a Specific Inhibitor of AKt Phosphorylation, in Adult Patients with Advanced Hematologic Malignancies. Blood. 110: 913-913. DOI: 10.1182/Blood.V110.11.913.913 |
0.408 |
|
| 2007 |
Faderl S, Thomas DA, Gandhi V, Borthakur G, Huang X, Plunkett W, Burger J, Cortes J, O’Brien S, Ravandi F, Bretz J, Kwari M, Kantarjian HM. Phase I/II Study of Clofarabine Plus Cyclophosphamide in Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL). Blood. 110: 4335-4335. DOI: 10.1182/Blood.V110.11.4335.4335 |
0.348 |
|
| 2007 |
Chen R, Wierda WG, Benaissa S, Hoch U, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of Action of SNS-032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol. Blood. 110: 3112-3112. DOI: 10.1182/Blood.V110.11.3112.3112 |
0.412 |
|
| 2007 |
Lamba J, Crews K, Pounds S, Schuetz E, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Deoxycytidine Kinase Genotype Influences Leukemia Cell Concentration of Cytarabine 5′-Triphosphate in Pediatric AML Patients. Blood. 110: 225-225. DOI: 10.1182/Blood.V110.11.225.225 |
0.343 |
|
| 2006 |
Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Research. 66: 10959-66. PMID 17108134 DOI: 10.1158/0008-5472.Can-06-1216 |
0.392 |
|
| 2006 |
Gandhi V, Plunkett W. Clofarabine and nelarabine: two new purine nucleoside analogs. Current Opinion in Oncology. 18: 584-90. PMID 16988579 DOI: 10.1097/01.Cco.0000245326.65152.Af |
0.342 |
|
| 2006 |
Moufarij MA, Sampath D, Keating MJ, Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood. 108: 4187-93. PMID 16954499 DOI: 10.1182/Blood-2006-05-023259 |
0.475 |
|
| 2006 |
Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4011-7. PMID 16818700 DOI: 10.1158/1078-0432.Ccr-05-2664 |
0.339 |
|
| 2006 |
Pelicano H, Carew JS, McQueen TJ, Andreeff M, Plunkett W, Keating MJ, Huang P. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia. 20: 610-9. PMID 16482209 DOI: 10.1038/Sj.Leu.2404140 |
0.363 |
|
| 2006 |
Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 107: 2517-24. PMID 16293603 DOI: 10.1182/Blood-2005-08-3351 |
0.457 |
|
| 2006 |
Quintas-Cardama A, Kantarjian HM, Wierda W, Ferrajoli A, Chen R, Ravandi F, Plunkett W, Cortes J. A Phase II Study of Intravenous (IV) Homoharringtonine (HHT) and Imatinib (IM) in Patients (pts) with Chronic Myeloid Leukemia (CML). Blood. 108: 2174-2174. DOI: 10.1182/Blood.V108.11.2174.2174 |
0.344 |
|
| 2005 |
Liu X, Guo Y, Li Y, Jiang Y, Chubb S, Azuma A, Huang P, Matsuda A, Hittelman W, Plunkett W. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer Research. 65: 6874-81. PMID 16061671 DOI: 10.1158/0008-5472.CAN-05-0288 |
0.315 |
|
| 2005 |
Khan SR, Nowak B, Plunkett W, Farquhar D. Bis(pivaloyloxymethyl) thymidine 5'-phosphate is a cell membrane-permeable precursor of thymidine 5'-phosphate in thymidine kinase deficient CCRF CEM cells. Biochemical Pharmacology. 69: 1307-13. PMID 15826601 DOI: 10.1016/J.Bcp.2005.02.008 |
0.314 |
|
| 2005 |
Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer. 103: 1985-95. PMID 15803490 DOI: 10.1002/Cncr.21005 |
0.42 |
|
| 2005 |
Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4079-88. PMID 15767648 DOI: 10.1200/Jco.2005.12.051 |
0.365 |
|
| 2005 |
Xiong HQ, Plunkett W, Wolff R, Du M, Lenzi R, Abbruzzese JL. A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 55: 559-64. PMID 15726370 DOI: 10.1007/S00280-004-0916-9 |
0.314 |
|
| 2005 |
Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, ... Plunkett W, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 105: 940-7. PMID 15486072 DOI: 10.1182/Blood-2004-05-1933 |
0.37 |
|
| 2005 |
Zeng Z, Konopleva M, Nowak BJ, Plunkett W, Borthakur G, Estey E, Champlin R, Bridger G, Andreeff M. Disruption of Leukemia/Stroma Cell Interactions by CXCR4 Antagonist AMD3465 Enhances Chemotherapy-Induced Apoptosis in AML. Blood. 106: 474-474. DOI: 10.1182/Blood.V106.11.474.474 |
0.404 |
|
| 2004 |
Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 103: 784-9. PMID 14551141 DOI: 10.1182/Blood-2003-06-2122 |
0.365 |
|
| 2004 |
Faderl S, Gandhi V, Verstovsek S, Cortes J, Ravandi-Kashani F, Beran M, Garcia-Manero G, Koller C, O’Brien S, Ferrajoli A, Estrov Z, Kwari M, Plunkett W, Kantarjian HM. Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood. 104: 875-875. DOI: 10.1182/Blood.V104.11.875.875 |
0.313 |
|
| 2004 |
Jabbour E, Verstovsek S, Gandhi V, Cortes J, Giles F, Koller C, O’Brien S, Plunkett W, Garcia-Manero G, Jackson E, Kantarjian H, Andreeff M. 2 Chlorodeoxyadenosine (2-CdA) and Cytarabine (ara-C) Combination Is Effective and Safe in Idiopathic Hypereosinophilic Syndrome (HES). Blood. 104: 4764-4764. DOI: 10.1182/Blood.V104.11.4764.4764 |
0.334 |
|
| 2003 |
Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene. 22: 9063-74. PMID 14663485 DOI: 10.1038/Sj.Onc.1207229 |
0.686 |
|
| 2003 |
Rao VA, Plunkett W. Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3204-12. PMID 12912974 |
0.627 |
|
| 2003 |
Yang LY, Jiang H, Rangel KM, Plunkett W. Cisplatin-induced ubiquitination of RNA polymerase II large subunit and suppression of induction by 7-hydroxystaurosporine (UCN-01). Oncology Reports. 10: 1489-95. PMID 12883729 DOI: 10.3892/Or.10.5.1489 |
0.403 |
|
| 2003 |
Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 102: 2379-86. PMID 12791647 DOI: 10.1182/Blood-2003-03-0925 |
0.358 |
|
| 2003 |
Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1167-73. PMID 12637486 DOI: 10.1200/Jco.2003.04.031 |
0.315 |
|
| 2003 |
Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood. 101: 4098-104. PMID 12531810 DOI: 10.1182/Blood-2002-08-2512 |
0.346 |
|
| 2002 |
Yamauchi T, Keating MJ, Plunkett W. UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Molecular Cancer Therapeutics. 1: 287-94. PMID 12467224 |
0.384 |
|
| 2002 |
Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clinical Pharmacokinetics. 41: 93-103. PMID 11888330 DOI: 10.2165/00003088-200241020-00002 |
0.321 |
|
| 2002 |
Zhou Y, Achanta G, Pelicano H, Gandhi V, Plunkett W, Huang P. Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response. Molecular Pharmacology. 61: 222-9. PMID 11752224 |
0.36 |
|
| 2001 |
Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation Journal of Clinical Oncology. 19: 3483-3489. PMID 11481354 DOI: 10.1200/Jco.2001.19.15.3483 |
0.339 |
|
| 2001 |
Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez C.O. J, Ramakrishna P, Rosner GL, Hodge JP, O'Brien S, Keating MJ. Evaluation of the combination of nelarabine and fludarabine in leukemias: Clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells Journal of Clinical Oncology. 19: 2142-2152. PMID 11304766 DOI: 10.1200/Jco.2001.19.8.2142 |
0.391 |
|
| 2001 |
Azuma A, Huang P, Matsuda A, Plunkett W. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Molecular Pharmacology. 59: 725-31. PMID 11259616 DOI: 10.1124/MOL.59.4.725 |
0.346 |
|
| 2000 |
Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 407: 390-5. PMID 11014196 DOI: 10.1038/35030140 |
0.384 |
|
| 2000 |
Huang P, Sandoval A, Van Den Neste E, Keating MJ, Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia. 14: 1405-13. PMID 10942236 DOI: 10.1038/Sj.Leu.2401845 |
0.455 |
|
| 2000 |
Feng L, Achanta G, Pelicano H, Zhang W, Plunkett W, Huang P. Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. International Journal of Molecular Medicine. 5: 597-604. PMID 10812007 DOI: 10.3892/Ijmm.5.6.597 |
0.317 |
|
| 2000 |
Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, Gandhi V. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 995-1003. PMID 10694549 DOI: 10.1200/Jco.2000.18.5.995 |
0.325 |
|
| 1999 |
Wilhelm M, O'Brien S, Rios MB, Estey E, Keating MJ, Plunkett W, Sorenson M, Kantarjian HM. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leukemia & Lymphoma. 34: 511-518. PMID 10492074 DOI: 10.3109/10428199909058478 |
0.346 |
|
| 1999 |
Aguayo A, Cortes JE, Kantarjian HM, Beran M, Gandhi V, Plunkett W, Kurtzberg J, Keating MJ. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer. 85: 58-64. PMID 9921974 DOI: 10.1002/(Sici)1097-0142(19990101)85:1<58::Aid-Cncr8>3.0.Co;2-E |
0.345 |
|
| 1998 |
Plunkett W. Biochemical modification related to repair DNA incorporation of Cytosine Arabinoside. Rinsho Yakuri\/Japanese Journal of Clinical Pharmacology and Therapeutics. 29: 223-224. DOI: 10.3999/Jscpt.29.223 |
0.392 |
|
| 1998 |
Consoli U, El-Tounsi I, Sandoval A, Snell V, Kleine H, Brown W, Robinson JR, DiRaimondo F, Plunkett W, Andreeff M. Differential Induction of Apoptosis by Fludarabine Monophosphate in Leukemic B and Normal T Cells in Chronic Lymphocytic Leukemia Blood. 91: 1742-1748. DOI: 10.1182/Blood.V91.5.1742.1742_1742_1748 |
0.349 |
|
| 1997 |
Li L, Keating MJ, Plunkett W, Yang LY. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Molecular Pharmacology. 52: 798-806. PMID 9351970 DOI: 10.1124/Mol.52.5.798 |
0.466 |
|
| 1997 |
Iwasaki H, Huang P, Keating MJ, Plunkett W. Differential Incorporation of Ara-C, Gemcitabine, and Fludarabine Into Replicating and Repairing DNA in Proliferating Human Leukemia Cells Blood. 90: 270-278. DOI: 10.1182/blood.V90.1.270 |
0.343 |
|
| 1996 |
Grégoire V, Hunter NR, Brock WA, Hittelman WN, Plunkett W, Milas L. Improvement in the therapeutic ratio of radiotherapy for a murine sarcoma by indomethacin plus fludarabine Radiation Research. 146: 548-553. PMID 8896581 DOI: 10.2307/3579555 |
0.312 |
|
| 1996 |
Loughlin S, Gandhi V, Plunkett W, Zwelling LA. The effect of 9-β-D-arabinofuranosyl-2-fluoroadenine and 1-β-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells Cancer Chemotherapy and Pharmacology. 38: 261-268. PMID 8646801 DOI: 10.1007/S002800050480 |
0.435 |
|
| 1996 |
Robertson LE, Denny AW, Huh YO, Plunkett W, Keating MJ, Nelson JA. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine. Cancer Chemotherapy and Pharmacology. 37: 445-50. PMID 8599867 DOI: 10.1007/S002800050410 |
0.357 |
|
| 1996 |
Gandhi V, Estey E, Keating M, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions Blood. 87: 256-264. DOI: 10.1182/blood.v87.1.256.256 |
0.332 |
|
| 1995 |
Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemotherapy and Pharmacology. 36: 181-8. PMID 7781136 DOI: 10.1007/BF00685844 |
0.357 |
|
| 1995 |
Gandhi V, Estey E, Plunkett W. Modulation of arabinosylcytosine metabolism during leukemia therapy Advances in Experimental Medicine and Biology. 370: 119-124. PMID 7544948 DOI: 10.1007/978-1-4615-2584-4_27 |
0.326 |
|
| 1995 |
Benvenuto JA, Hittelman WN, Zwelling LA, Plunkett W, Pandita TK, Farquhar D, Newman RA. Biochemical pharmacology of penclomedine (NSC-338720) Biochemical Pharmacology. 50: 1157-1164. PMID 7488229 DOI: 10.1016/0006-2952(95)00251-T |
0.348 |
|
| 1994 |
Ellis AL, Nowak B, Plunkett W, Zwelling LA. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent. Cancer Chemotherapy and Pharmacology. 34: 249-56. PMID 8004759 DOI: 10.1007/BF00685085 |
0.324 |
|
| 1994 |
Gandhi V, Huang P, Plunkett W. Fludarabine inhibits DNA replication: A rationale for its use in the treatment of acute leukemias Leukemia and Lymphoma. 14: 3-9. PMID 7881348 DOI: 10.3109/10428199409052689 |
0.338 |
|
| 1994 |
Keating MJ, O'brien S, Robertson LE, Kantarjian H, Dimopoulos M, Mclaughlin P, Cabanillas F, Gregoire V, Ying-Yang L, Gandhi V, Estey E, Plunkett W. The expanding role of fludarabine in hematologic malignancies. Leukemia & Lymphoma. 14: 11-16. PMID 7533576 DOI: 10.3109/10428199409052690 |
0.419 |
|
| 1993 |
Gandhi V, Estey E, Keating MJ, Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias Leukemia and Lymphoma. 10: 109-114. PMID 8481660 DOI: 10.3109/10428199309149122 |
0.371 |
|
| 1993 |
Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 116-24. PMID 8418222 DOI: 10.1200/Jco.1993.11.1.116 |
0.324 |
|
| 1993 |
Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia & Lymphoma. 9: 343-350. PMID 8394169 DOI: 10.3109/10428199309148532 |
0.315 |
|
| 1993 |
Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer. 72: 2155-2160. PMID 8374873 DOI: 10.1002/1097-0142(19931001)72:7<2155::Aid-Cncr2820720715>3.0.Co;2-V |
0.377 |
|
| 1993 |
Robertson LE, Hall R, Keating MJ, Estey E, Kantarjian HM, McLaughlin P, Hagemeister FB, Plunkett W. High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. Leukemia & Lymphoma. 10: 43-8. PMID 8374522 DOI: 10.3109/10428199309147355 |
0.369 |
|
| 1993 |
Huang P, Plunkett W. A quantitative assay for fragmented DNA in apoptotic cells. Analytical Biochemistry. 207: 163-7. PMID 1489090 DOI: 10.1016/0003-2697(92)90518-C |
0.309 |
|
| 1993 |
Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 81: 2878-2884. DOI: 10.1182/Blood.V81.11.2878.Bloodjournal81112878 |
0.335 |
|
| 1993 |
Robertson L, Chubb S, Meyn R, Story M, Ford R, Hittelman W, Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2- chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine Blood. 81: 143-150. DOI: 10.1182/blood.v81.1.143.143 |
0.335 |
|
| 1992 |
Gandhi V, Huang P, Xu YZ, Heinemann V, Plunkett W. Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity. Advances in Experimental Medicine and Biology. 125-30. PMID 1789190 DOI: 10.1007/978-1-4899-2638-8_28 |
0.337 |
|
| 1992 |
Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 10: 406-13. PMID 1740680 DOI: 10.1200/Jco.1992.10.3.406 |
0.308 |
|
| 1992 |
Gandhi V, Plunkett W. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells Cancer Chemotherapy and Pharmacology. 31: 11-17. PMID 1458554 DOI: 10.1007/Bf00695988 |
0.349 |
|
| 1992 |
Xu YZ, Plunkett W. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine. Biochemical Pharmacology. 44: 1819-27. PMID 1449536 DOI: 10.1016/0006-2952(92)90077-V |
0.376 |
|
| 1989 |
Heinemann V, Estey E, Keating MJ, Plunkett W. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 622-8. PMID 2709090 DOI: 10.1200/Jco.1989.7.5.622 |
0.315 |
|
| 1988 |
Heinemann V, Murray D, Walters R, Meyn RE, Plunkett W. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemotherapy and Pharmacology. 22: 205-10. PMID 3165725 DOI: 10.1007/Bf00273412 |
0.366 |
|
| 1987 |
Plunkett W, Liliemark JO, Estey E, Keating MJ. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Seminars in Oncology. 14: 159-166. DOI: 10.5555/Uri:Pii:0093775487900613 |
0.323 |
|
| 1986 |
Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. The American Journal of Medicine. 81: 387-94. PMID 3463209 DOI: 10.1016/0002-9343(86)90287-1 |
0.346 |
|
| 1984 |
Kantarjian H, Barlogie B, Plunkett W, Velasquez W, McLaughlin P, Riggs S, Cabanillas F. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 1: 689-94. PMID 6366130 DOI: 10.1200/Jco.1983.1.11.689 |
0.342 |
|
| 1977 |
Plunkett W, Cohen SS. Penetration of mouse fibroblasts by 2' deoxyadenosine 5' phosphate and incorporation of the nucleotide into DNA Journal of Cellular Physiology. 91: 261-270. PMID 558986 DOI: 10.1002/Jcp.1040910211 |
0.404 |
|
| Show low-probability matches. |